TY - JOUR
T1 - GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice
AU - Arai, Sawako
AU - Takuma, Kazuhiro
AU - Mizoguchi, Hiroyuki
AU - Ibi, Daisuke
AU - Nagai, Taku
AU - Kamei, Hiroyuki
AU - Kim, Hyoung Chun
AU - Yamada, Kiyofumi
N1 - Funding Information:
This study was supported in part by a Grant-in-Aid for Scientific Research (No.19390062) from the Japan Society for the Promotion of Science and grants for the 21st century COE program from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Smoking Research Foundation, Japan, the JSPS and KOSEF under the Japan–Korea Basic Scientific Cooperation Program, the Academic Frontier Project for Private Universities; matching fund subsidy from MEXT, 2007–2011, and the Research on Risk of Chemical Substances, Health and Labour Science Research Grants supported by Ministry of Health, Labour and Welfare, and JST, CREST.
PY - 2009/1/5
Y1 - 2009/1/5
N2 - In this study, we investigated the effects of GABAA and GABAB receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABAB receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABAA receptor agonist, had no significant effect. GABAB receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.
AB - In this study, we investigated the effects of GABAA and GABAB receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABAB receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABAA receptor agonist, had no significant effect. GABAB receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.
UR - http://www.scopus.com/inward/record.url?scp=57249108189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57249108189&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2008.10.065
DO - 10.1016/j.ejphar.2008.10.065
M3 - Article
C2 - 19028488
AN - SCOPUS:57249108189
VL - 602
SP - 101
EP - 104
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 1
ER -